Screening for idiopathic pulmonary fibrosis using comorbidity signatures in electronic health records-Reference-Cited by-同舟云学术

Screening for idiopathic pulmonary fibrosis using comorbidity signatures in electronic health records

Published:2022-09-29 Issue:10 Volume:28 Page:2107-2116
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Onishchenko Dmytro^ORCID,Marlowe Robert J.^ORCID,Ngufor Che G.,Faust Louis J.,Limper Andrew H.,Hunninghake Gary M.,Martinez Fernando J.,Chattopadhyay Ishanu^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.nature.com/articles/s41591-022-02010-y.pdf

Reference82 articles.

1. Lederer, D. & Martinez, F. Idiopathic pulmonary fibrosis. N. Engl. J. Med. 378, 1811–1823 (2018).

2. Raghu, G., Remy-Jardin, M. & Myers, J. Diagnosis of idiopathic pulmonary fibrosis. an official ats/ers/jrs/alat clinical practice guideline. Am. J. Respir. Crit. Care Med. 198, 44–68 (2018).

3. Raghu, G. Idiopathic pulmonary fibrosis: shifting the concept to irreversible pulmonary fibrosis of many entities. Lancet Respir. Med. 7, 926–929 (2019).

4. Ley, B., Collard, H. & King, T., Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 183, 431–440 (2011).

5. Antoniou, K., Symvoulakis, E., Margaritopoulos, G., Lionis, C. & Wells, A. Early diagnosis of IPF: time for a primary-care case-finding initiative? Lancet Respir. Med. 2, 1 (2014).

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ELIPF: Explicit Learning Framework for Pre-Emptive Forecasting, Early Detection and Curtailment of Idiopathic Pulmonary Fibrosis Disease;BioMedInformatics;2024-08-01

2. Integrated ML-Based Strategy Identifies Drug Repurposing for Idiopathic Pulmonary Fibrosis;ACS Omega;2024-06-27

3. The diagnostic pathway for patients with interstitial lung disease: a mixed-methods study of patients and physicians;BMJ Open Respiratory Research;2024-04

4. Comprehensive review of potential drugs with anti-pulmonary fibrosis properties;Biomedicine & Pharmacotherapy;2024-04

5. Pulmonary Fibrosis Stakeholder Summit: A Joint National Heart, Lung, and Blood Institute, Three Lakes Foundation, and Pulmonary Fibrosis Foundation Workshop Report;American Journal of Respiratory and Critical Care Medicine;2023-12-19